Roche partners with Zealand Pharma to push forward obesity drug

LONDON — Looking to expand its obesity offerings, Roche on Wednesday said it had partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion in upfront cash.

The Swiss pharma giant and the Danish biotech will now work together to develop Zealand’s drug candidate petrelintide, aiming to test it on its own and in combination with Roche’s experimental CT-388.

The agreement includes additional payments based on certain clinical and sales goals being met, totaling up to $5.3 billion.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Marty Makary, Trump nominee to lead FDA, pledges to avoid conflicts if confirmed

WASHINGTON — Marty Makary, President Trump’s pick to be Food and Drug Administration commissioner, promised to step down as an adviser to various health tech,

March 3, 2025

What’s on the Horizon for Myasthenia Gravis

While the medical armamentarium for generalized myasthenia gravis (gMG) has blossomed in the last several years, further advances are headed down the pipeline. Atop standard

November 7, 2023

Montana looks to become latest state to boost nonprofit hospital oversight

Montana’s proposal to increase oversight is part of a national trend by states to ensure nonprofit hospitals act as charitable organizations as they claim tax-exempt

July 25, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.